Avacta plc Investor Webinar

Investor webinar presented by Dr. Alastair Smith, Chief Executive Officer, Avacta Group plc (AIM: AVCT) a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics and chaired by experienced news and corporate events presenter Katie Pilbeam (www.katiepilbeam.com).

The webinar covered the Company’s updated clinical data from the first-in-human Phase 1 trial of AVA6000, the first of the Company’s pre|CISION™ peptide drug conjugates that targets chemotherapy to the tumour, which were be presented at the 2024 American Association for Cancer Research Annual Meeting, taking place in San Diego, California from 5-10 April 2024. The updated clinical data was presented in the Phase 1 Clinical Trials 2 Poster Session on 9 April 2024.

Turner Pope Investments hosted the Investor Webinar on Wednesday 10th April 2024.

Read our latest research note on Avacta Group plc published on the 29th February 2024:

Access our research notes: